{"entity":{"id":"nct06649708","kind":"trial","name":"HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies","aka":[],"tldr":"A phase 1/2 trial of HX044 in advanced solid tumours, run by Hanx Biopharmaceuticals (Wuhan) Co., Ltd., now recruiting.","summary":"HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT06649708 by Hanx Biopharmaceuticals (Wuhan) Co., Ltd., with 100 participants planned, started 2024-12-30 and due to reach its primary completion in 2025-10-31. Interventions recorded: HX044.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06649708","url":"https://clinicaltrials.gov/study/NCT06649708"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hangzhou-hanx-biopharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06649708","phase":"1/2","setting":"A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies","sponsor":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd.","started":"2024-12-30","startedType":"actual","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06649708/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hangzhou-hanx-biopharmaceuticals","kind":"company","name":"Hangzhou Hanx Biopharmaceuticals","route":"/companies/hangzhou-hanx-biopharmaceuticals/"}]}}